|
News For ENDP;COV;ABT;ACT;TEVA From The Last 14 Days Check below for free stories on ENDP;COV;ABT;ACT;TEVA the last two weeks. |
|
|
| May 20, 2013 |
| 16:51 EDT |  | ACT | Actavis, Warner Chilcott deal includes $160M termination fee
 Subscribe for More Information |
|
| 16:22 EDT |  | ACT | On The Fly: Closing Wrap
Subscribe for More Information |
|
| 14:27 EDT |  | ACT | Actavis price target raised to $140 from $101 at Morgan Stanley
Morgan Stanley raised Actavis's price target to $140 due to Warner Chilcott (WCRX) deal accretion. Shares are Overweight rated. |
|
| 13:06 EDT | | ACT | On The Fly: Midday Wrap
Stocks on Wall Street were modestly higher at midday as the Dow and S&P seek to continue their march higher after closing last week at record levels. ECONOMIC EVENTS: In the U.S., the light domestic economic calendar included the Chicago Fed National Activity index, which slipped to -0.53 for April from its prior reading of -0.23. In Asia, the Hang Seng and Shanghai Composite both climbed after Chinese home prices were reported to have risen in April. COMPANY NEWS: Yahoo (YHOO) confirmed it is buying social media platform Tumblr for $1.1B, as widely reported over the weekend, and promised "not to screw it up" in its press release to announce the deal... Actavis (ACT) agreed to acquire Warner Chilcott (WCRX) in a stock-for-stock transaction valued at approximately $8.5B. The deal, which was approved by the boards of both companies, equates to a value of $20.08 per Warner Chilcott share based on Actavis' closing share price on Friday, the companies said. MAJOR MOVERS: Among the notable gainers were some other companies with M&A news: Acquity Group (AQ) shares more than doubled after Accenture (ACN) agreed to buy the company for $13.00 per American Depositary Share, and Pactera Technology (PACT) gained 31% after receiving a non-binding proposal from a Blackstone (BX) affiliate to be taken private for $7.50 per ADS. Among the noteworthy losers was XenoPort (XNPT), which fell 11% after one of its drugs failed in a Phase III trial for multiple sclerosis spasticity. Also lower were shares of Red Hat (RHT), which slid 4% following a downgrade to Market Perform at BMO Capital. INDICES: Near 1 pm ET, the Dow was up 13.67, or 0.09%, to 15,368.07; the Nasdaq was up 1.13, or 0.03%, to 3,500.10; and the S&P 500 was up 2.18, or 0.13%, to 1,669.65. |
|
| 11:27 EDT | | TEVA | Appeals court reverses, remands patent ruling in Sanofi suit against Mylan, Teva
Subscribe for More Information |
|
| 11:16 EDT | | ACT | Actavis, Warner Chilcott company worth $128 per share, says Leerink
Leerink estimates the value of the combined Actavis (ACT) and Warner Chilcott (WCRX) company at $128 per share. The firm sees some upside for shareholders of the new company should Warner Chilcott's brands prove durable in 2014. Leerink has a Market Perform on shares of Actavis. |
|
| 10:43 EDT | | ACT | Actavis price target rasied to $145 from $124 at BMO Capital
Subscribe for More Information |
|
| 10:11 EDT |  | ABT | On The Fly: Analyst Upgrade Summary
Subscribe for More Information |
|
| 09:57 EDT |  | ACT | Actavis hosted a conference call
Subscribe for More Information |
|
| 09:26 EDT | | ACT | On The Fly: Pre-market Movers
Subscribe for More Information |
| |
| 08:05 EDT | | COV | Covidien receives FDA 510(k) clearance for Nellcor pulse oximetry motion claims
Subscribe for More Information |
|
| 07:21 EDT |  | ACT | Warner Chilcott volatility elevated into Actavis acquiring for $8.5B
Subscribe for More Information |
|
| 07:11 EDT | | ACT | Actavis to acquire Warner Chilcott for $8.5B in stock
Subscribe for More Information |
|
| 07:08 EDT | | ACT | Actavis to acquire Warner Chilcott in $8.5B stock-for-stock transaction
Subscribe for More Information |
|
| 06:01 EDT | | ABT | Abbott upgraded to Buy from Neutral at Goldman
Goldman upgraded Abbott to reflect accelerating growth driven by emerging markets, better growth and product mix, new product launches, and market share gains. Price target raised to $44 from $38. |
|
| May 17, 2013 |
| 14:48 EDT |  | ACT | Actavis may bid for Warner Chilcott to ward off takeover, Reuters says
Subscribe for More Information |
|
| 13:56 EDT | | ACT | Actavis may purchase Warner Chilcott as takeover defense, Reuters reports
Over past few weeks, Actavis (ACT) has "spurned approaches" from Valeant (VRX) and Mylan (MYL), and has instead pursued a bid for Warner Chilcott (WCRX), according to Reuters, citing people familiar with the situation. |
|
| 11:53 EDT | | ENDP | Options with decreasing implied volatility: SGMO ARNA CSC ENDP
Subscribe for More Information |
|
| May 16, 2013 |
| 10:03 EDT | | ENDP | On The Fly: Analyst Upgrade Summary
Subscribe for More Information |
|
| 08:27 EDT | | ENDP | Endo Health upgraded to Buy from Neutral at Buckingham
Buckingham upgraded Endo Health based on attractive risk/reward and expectations for a more detailed strategy from the new CEO, maybe by Q2 results. Price target remains $41. |
| |
|
|
|
|
